<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">456</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2022-9-3-38-48</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Matrix metalloproteinases and heat shock proteins on extracellular vesicles in colorectal cancer patients: association with metabolic status</article-title><trans-title-group xml:lang="ru"><trans-title>Матриксные металлопротеиназы и белки теплового шока на внеклеточных везикулах у больных колоректальным раком: связь с метаболическим статусом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4595-4177</contrib-id><name-alternatives><name xml:lang="en"><surname>Yunusova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Юнусова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009; 2 Moskovskiy Tract, Tomsk 634050.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5; 634050 Томск, Московский тракт, 2.</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Svarovsky</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Сваровский</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dmitry A. Swarovski.</p><p>2 Moskovskiy Tract, Tomsk 634050.</p></bio><bio xml:lang="ru"><p>Сваровский Дмитрий Андреевич.</p><p>634050 Томск, Московский тракт, 2.</p></bio><email>svarovsky.d.a@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dandarova</surname><given-names>E. E.</given-names></name><name xml:lang="ru"><surname>Дандарова</surname><given-names>Е. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>2 Moskovskiy Tract, Tomsk 634050.</p></bio><bio xml:lang="ru"><p>634050 Томск, Московский тракт, 2.</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kostromitsky</surname><given-names>D. N.</given-names></name><name xml:lang="ru"><surname>Костромицкий</surname><given-names>Д. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dimcha</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Димча</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7234-4708</contrib-id><name-alternatives><name xml:lang="en"><surname>Cheremisina</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Черемисина</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4701-0375</contrib-id><name-alternatives><name xml:lang="en"><surname>Afanasiev</surname><given-names>S. G.</given-names></name><name xml:lang="ru"><surname>Афанасьев</surname><given-names>С. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Konovalov</surname><given-names>A. I.</given-names></name><name xml:lang="ru"><surname>Коновалов</surname><given-names>А. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4345-7719</contrib-id><name-alternatives><name xml:lang="en"><surname>Startseva</surname><given-names>Z. A.</given-names></name><name xml:lang="ru"><surname>Старцева</surname><given-names>Ж. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0947-8778</contrib-id><name-alternatives><name xml:lang="en"><surname>Kondakova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Кондакова</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2865-7576</contrib-id><name-alternatives><name xml:lang="en"><surname>Patysheva</surname><given-names>M. R.</given-names></name><name xml:lang="ru"><surname>Патышева</surname><given-names>М. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9853-223X</contrib-id><name-alternatives><name xml:lang="en"><surname>Grigor'eva</surname><given-names>A. E.</given-names></name><name xml:lang="ru"><surname>Григорьева</surname><given-names>А. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>8 Prospekt Akademika Lavrent'eva, Novosibirsk 630090.</p></bio><bio xml:lang="ru"><p>630090 Новосибирск, проспект Академика Лаврентьева, 8.</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Spirina</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Спирина</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5 Kooperativny Line, Tomsk 634009; 2 Moskovskiy Tract, Tomsk 634050.</p></bio><bio xml:lang="ru"><p>634009, Томск, Кооперативный пер., 5; 634050 Томск, Московский тракт, 2.</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Tomsk National Research Medical Center of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт онкологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Siberian State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute of Chemical Biology and Fundamental Medicine of the Siberian branch of Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2022</year></pub-date><volume>9</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>38</fpage><lpage>48</lpage><history><date date-type="received" iso-8601-date="2022-10-07"><day>07</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-10-07"><day>07</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Yunusova N.V., Svarovsky D.A., Dandarova E.E., Kostromitsky D.N., Dimcha A.A., Cheremisina O.V., Afanasiev S.G., Konovalov A.I., Startseva Z.A., Kondakova I.V., Patysheva M.R., Grigor'eva A.E., Spirina L.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Юнусова Н.В., Сваровский Д.А., Дандарова Е.Э., Костромицкий Д.Н., Димча А.А., Черемисина О.В., Афанасьев С.Г., Коновалов А.И., Старцева Ж.А., Кондакова И.В., Патышева М.Р., Григорьева А.Е., Спирина Л.В.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Yunusova N.V., Svarovsky D.A., Dandarova E.E., Kostromitsky D.N., Dimcha A.A., Cheremisina O.V., Afanasiev S.G., Konovalov A.I., Startseva Z.A., Kondakova I.V., Patysheva M.R., Grigor'eva A.E., Spirina L.V.</copyright-holder><copyright-holder xml:lang="ru">Юнусова Н.В., Сваровский Д.А., Дандарова Е.Э., Костромицкий Д.Н., Димча А.А., Черемисина О.В., Афанасьев С.Г., Коновалов А.И., Старцева Ж.А., Кондакова И.В., Патышева М.Р., Григорьева А.Е., Спирина Л.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/456">https://umo.abvpress.ru/jour/article/view/456</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold>. In most patients with colorectal cancer (CRC), the tumor develops against the background of metabolically healthy obesity or metabolic syndrome (more than 60 % of patients), the key pathogenetic moment of which is developing hyperinsulinemia. Metabolic changes are also characteristic of patients with colon polyps (CP), which are currently considered as the most significant precancerous diseases. It has been shown that fractions of small extracellular vesicles (EVs) of adipocyte origin are specifically enriched in extracellular matrix proteins, including matrix metalloproteinases (MMPs), chaperones, and some metabolic enzymes involved in the synthesis of lipids and carbohydrates. This was the reason for choosing exosomal markers in our study. Comparison of protein expression on CD9- and FABP-4 positive vesicles will be useful to explain some clinical issues, such as the effectiveness of thermoradiotherapy or radiotherapy in obese CRC patients; for a more substantiated search for vesicular prognostic markers in obese cancer patients. However, taking into account the lack of data in the literature on the level of MMPs and HSPs expression in the composition of the total pool of EVs and in the composition of FABP4-positive EVs in patients with PTC and CRC patients, the aim of the work was formulated.</p><p><bold>Aim</bold>. Study of the level of MMPs and heat shock proteins (HSPs) on CD9- and FABP4-positive EVs in patients with CP and CRC in relation to metabolic status.</p><p><bold>Materials and methods</bold>. The study included 12 patients with CRC (T2-4N0-2M0; mean age 59.6 ± 1.6 years) who were treated at the Department of Abdominal Oncology of the Cancer Research Institute of the Tomsk National Research Medical Center from 2019 to 2021. The comparison group included 10 patients with CP. The level of proteins on the surface of CD9- and FABP4-positive EVs was studied using flow cytometry.</p><p><bold>Results</bold>. MMP9-positive EVs were detected more often in CRC patients than in CP patients, however, MMP9+MMP2+TIMP-positive EVs were significantly more frequently detected in CP patients. Among the studied heat shock proteins, HSP60 was most often expressed on the surface of EVs, and HSP60-positive EVs were detected on the surface of CD9-positive exosomes in patients with PTC much more often than in CRC. In patients with CRC, compared with patients with СP, among FABP4-positive EVs, the proportion of triple-positive EVs and EVs with the MMP9+MMP2-TIMP1+ phenotype significantly increases, which in general may indicate overexpression of MMP9 and TIMP1 by adipocytes or marcrophages of adipose tissue in patients with CRC. Correlation analysis revealed multiple correlations of individual phenotypes of CD9-positive EVs in patients with CRC with body mass index and serum high density lipoprotein cholesterol levels, while the phenotypes of FABP4-positive EVs were associated mainly with triglyceride levels.</p><p><bold>Conclusions</bold>. The phenotypes of CD9-positive and FABP4-positive circulating EVs are promising as predictors for clarifying cancer risk in patients with colon polyps, as well as in terms of explaining the effectiveness of the treatment of CRC patients with obesity or metabolic syndrome.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. У большинства больных колоректальным раком (КРР) опухоль возникает на фоне метаболически здорового ожирения, или метаболического синдрома (более чем в 60 % случаев), ключевым патогенетическим моментом которого является развивающаяся гиперинсулинемия. метаболические изменения также характерны для больных с полипами толстой кишки (ПТК), которые в настоящее время рассматриваются как наиболее значимые предраковые заболевания. показано, что фракции малых внеклеточных везикул (ВВ) адипоцитарного происхождения специфически обогащены белками внеклеточного матрикса, включая матриксные металлопротеиназы (MMPs), шаперонами, а также некоторыми метаболическими ферментами, участвующими в синтезе липидов и углеводов. это послужило причиной выбора экзосомальных маркеров в нашем исследовании. Сравнение экспрессии протеинов на CD9-и FABP4-позитивных ВВ будет полезно для объяснения некоторых клинических моментов, например эффективности терморадиотерапии или радиотерапии у больных КРР с ожирением, а также для более обоснованного поиска везикулярных прогностических маркеров у онкологических пациентов с ожирением. цель исследования была сформулирована с учетом отсутствия в литературе данных об уровне экспрессии MMPs и белков теплового шока (HSPs) в составе тотального пула ВВ и в FABP4-позитивных ВВ у пациентов с ПТК и КРР.</p><p><bold>Цель исследования</bold> - изучение уровня MMPs и HSPs на CD9- и FABP4-позитивных ВВ у пациентов с ПТК и КРР во взаимосвязи с метаболическим статусом.</p><p><bold>Материалы и методы</bold>. В исследование были включены 12 больных КРР (T2-4N0-2M0; средний возраст 59,6 ± 1,6 года), проходивших лечение в отделении абдоминальной онкологии Научно-исследовательского института онкологии Томского национального исследовательского медицинского центра Российской академии наук с 2019 по 2021 г. В группу сравнения вошли 10 пациентов с ПТК. Уровень белков на поверхности CD9- и FABP4-позитивных ВВ был изучен с помощью проточной цитометрии.</p><p><bold>Результаты</bold>. ММР9-позитивные ВВ чаще выявлялись у больных КРР по сравнению с пациентами с ПТК, однако ММР9+ММР2+Т1МР-позитивные ВВ достоверно чаще обнаруживались у последних. Из изученных белков теплового шока на поверхности ВВ наиболее часто экспрессировался HSP60, причем HSP60-позитивные ВВ выявлялись на поверхности CD9-позитивных экзосом при ПТК гораздо чаще, чем при КРР. У больных КРР по сравнению с пациентами с ПТК среди FABP4-позитивных ВВ наблюдалось существенное увеличение доли трипл-позитивных ВВ и ВВ с фенотипом MMP9+MMP2-TIMP1+, что в целом может свидетельствовать о гиперэкспрессии MMP9 и TIMP1 адипоцитами или маркрофагами жировой ткани у больных КРР. Корреляционный анализ выявил множественные связи отдельных фенотипов CD9-позитивных ВВ у больных КРР с индексом массы тела и уровнем холестерина липопротеинов высокой плотности в сыворотке крови, в то время как фенотипы FABP4-позитивных ВВ были ассоциированы в основном с уровнем триглицеридов.</p><p><bold>Заключение</bold>. Фенотипы CD9-позитивных и FABP4-позитивных циркулирующих ВВ перспективны в качестве предикторов для уточнения онкологического риска у больных с полипами толстой кишки, а также в плане объяснения эффективности лечения больных КРР с ожирением или метаболическим синдромом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>matrix metalloproteinases</kwd><kwd>heat shock proteins</kwd><kwd>adipose tissue</kwd><kwd>extracellular vesicles</kwd><kwd>FABP4</kwd><kwd>colorectal cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>матриксные металлопротеиназы</kwd><kwd>белки теплового шока</kwd><kwd>жировая ткань</kwd><kwd>внеклеточные везикулы</kwd><kwd>FABP4</kwd><kwd>колоректальный рак</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was conducted within the framework of the grant of the Siberian State Medical University, Ministry of Health of Russia “Molecular and biochemical mechanisms of the development of infectious and non-infectious somatic diseases based on the regulation of proteolysis and the formation of metabolic disorders”. When performing this study, the equipment of the Center for Collective Use “Medical Genomics” (Tomsk National Research Medical Center of the Russian Academy of Sciences) was used.</funding-statement><funding-statement xml:lang="ru">Исследование проведено в рамках гранта ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России «Молекулярные и биохимические механизмы развития инфекционных и неинфекционных соматических заболеваний на основе регуляции протеолиза и формирования метаболических нарушений». При выполнении данного исследования использовалось оборудование Центра коллективного пользования «Медицинская геномика» (ФГБНУ «Томский национальный медицинский исследовательский центр Российской академии наук»).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Yunusova N.V., Kondakova I.V., Kolomiets L.A. et al. The role of metabolic syndrome variant in the malignant tumors progression. Diabetes Metab Syndr 2018;12(5):807-12. DOI: 10.1016/j.dsx.2018.04.028</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Yunusova N.V., Kondakova I.V., Kolomiets L.A. et al. Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors). Asia Pac J Clin Oncol 2018;14(3):134-40. DOI: 10.1111/ajco.12780</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Wang J., Wu Y., Guo J. et al. Adipocyte-derived exosomes promote lung cancer metastasis by increasing MMP9 activity via transferring MMP3 to lung cancer cells. Oncotarget 2017;8(47):81880-91. DOI: 10.18632/oncotarget.18737</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bouloumie A., Sengenes C., Portolan G. et al. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001;50(9):2080—6. DOI: 10.2337/diabetes.50.9.2080</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Weisberg S.P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112(12):1796-808. DOI: 10.1172/JCI19246</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Gao X., Salomon C., Freeman D.J. et al. Extracellular vesicles from adipose tissue — a potential role in obesity and type 2 diabetes? Front Endocrinol (Lausanne) 2017;8:202. DOI: 10.3389/fendo.2017.00202</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Furuhashi M. Fatty Acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb 2019;26(3):216-32. DOI: 10.5551/jat.48710</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Eguchi A., Lazic M., Armando A.M. et al. Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress. J Mol Med (Berl) 2016;94(11):1241-53. DOI: 10.1007/s00109-016-1446-8</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>DeClercq V., d'Eon B., McLeod R.S. Fatty acids increase adiponectin secretion through both classical and exosome pathways. Biochim Biophys Acta 2015;1851(9):1123—33. DOI: 10.1016/j.bbalip.2015.04.005</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kralisch S., Ebert T., Lossner U. et al. Adipocyte fatty acid-binding protein is released from adipocytes by a non-conventional mechanism. Int J Obes (Lond) 2014;38(9):1251-4. DOI: 10.1038/ijo.2013.232</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Durcin M., Fleury A., Taillebois E. et al. Characterisation of adipocyte-derived extracellular vesicle subtypes identifies distinct protein and lipid signatures for large and small extracellular vesicles. J Extracell Vesicles 2017;6(1):1305677. DOI: 10.1080/20013078.2017.1305677</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Tamkovich S.N., Yunusova N.V., Stakheeva M.N. et al. Isolation and characterization of blood plasma in patients with breast cancer and colorectal cancer. Biomedicinskaya Khimiya = Biomedical Chemistry 2017;63(2):165—9. (in Russ.). DOI: 10.18097/PBMC20176302165</mixed-citation><mixed-citation xml:lang="ru">Тамкович С.Н., Юнусова Н.В., Стахеева М.Н. и др. Выделение и характеристика экзосом плазмы крови больных раком молочной железы и колоректальным раком. Биомедицинская химия 2017;63(2):165—9. DOI: 10.18097/PBMC20176302165</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Tamkovich S.N., Yunusova N.V., Somov A.K. et al. Comparative sub-population analysis of exosomes from blood plasma of cancer patients. Biomedicinskaya Khimiya = Biomedical Chemistry 2018;64(1):110-4. (In Russ.). DOI: 10.18097/PBMC20186401110</mixed-citation><mixed-citation xml:lang="ru">Тамкович С.Н., Юнусова Н.В., Сомов А.К. и др. Сравнительный субпопуляционный анализ экзосом плазмы крови больных злокачественными новообразованиями. Биомедицинская химия 2018;64(1):110-4. DOI: 10.18097/PBMC20186401110</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><mixed-citation>Yunusova N.V., Zambalova E.A., Patysheva M.R. et al. Exosomal protease cargo as prognostic biomarker in colorectal cancer. Asian Pac J Cancer Prev 2021;22(3):861-9. DOI: 10.31557/APJCP.2021.22.3.861</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Matthews A.L., Noy P.J., Reyat J.C. Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: the emerging role of tetraspanins and rhomboids. Platelets 2017;28(4):333-41. DOI: 10.1080/09537104.2016.1184751</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gutwein P., Stoeck A., Riedle S. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 2005;11(7):2492-501. DOI: 10.1158/1078-0432.CCR-04-1688</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Buzas E.I., Tot E.A., Sodar B.V. Molecular interactions at the surface of extracellular vesicles. Semin Immunopathol 2018;40(5):453-64. DOI: 10.1007/s00281-018-0682-0</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Shimoda M., Khokha R. Metalloproteinases in extracellular vesicles. Biochim Biophys Acta Mol Cell Res 2017;1864(11 Pt. A):1989-2000. DOI: 10.1016/j.bbamcr.2017.05.027</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ginestra A., Monea S., Seghezzi G. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 1997;272(27):17216-22. DOI: 10.1074/jbc.272.27.17216</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kaur P., Hurwitz M.D., Krishnan S. et al. Combined hyperthermia and radiotherapy for the treatment of cancer. Cancers (Basel) 2011;3(4):3799-823. DOI: 10.3390/cancers3043799</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Taha E.A., Ono K., Eguchi T. Roles of extracellular HSPs as biomarkers in immune surveillance and immune evasion. Int J Mol Sci 2019;20(18):4588. DOI: 10.3390/ijms20184588</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Lv L.H., Wan Y.L., Lin Y. et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem 2012;287(19):15874-85. DOI: 10.1074/jbc.M112.340588</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Bavisotto C.C., Cipolla C., Graceffa G. et al. Immumirphological pattern of molecular chaperones in normal and pathological thyroid tissues and circulating exosomes: potential use in clinics. Int J Mol Sci 2019;20(18):4496. DOI: 10.3390/ijms20184496</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hubal M.J., Nadler E.P., Ferrante S.C. et al. Circulating adipocyte-derived exosomal MicroRNAs associated with decreased insulin resistance after gastric bypass. Obesity (Silver Spring) 2017;25(1):102-10. DOI: 10.1002/oby.21709</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Gustafson C.M., Shepherd A.J., Miller V.M., Jayachandran M. Age-and sex-specific differences in blood-borne microvesicles from apparently healthy humans. Biol Sex Differ 2015;6:10. DOI: 10.1186/s13293-015-0028-8</mixed-citation></ref></ref-list></back></article>
